Health condition · Clinically reviewed
Chronic kidney disease, stages, monitoring and medications that slow progression.
Reduced kidney function detected on blood or urine tests. Modern medications (SGLT2 inhibitors, ARBs, finerenone) meaningfully slow progression when caught early.
Why trust this guide
- 01
Clinically reviewed
Written by our editorial team and reviewed by a registered UK clinician before publication.
- 02
Sourced, not summarised
Every claim is checked against NICE, KDIGO or a peer-reviewed source you can see at the end.
- 03
Updated for 2026
Reflects current UK guidance on CKD staging, SGLT2 inhibitors and progression-slowing medications.
Key facts
Chronic kidney disease at a glance.
The essentials, in plain English — what CKD is, how it is staged, what causes it and how it is treated in the UK today.
-
What it is
eGFR under 60 mL/min/1.73m² for more than 3 months, or a urine ACR of 3 mg/mmol or above.
-
How it is staged
By eGFR (G1–G5) and by urine albumin (A1–A3) — both matter for prognosis.
-
Top causes
Diabetes and hypertension account for the majority of UK CKD cases.
-
First-line drug shift
SGLT2 inhibitors are now standard in CKD, including in people without diabetes.
-
Risk of progression
The Kidney Failure Risk Equation (KFRE) estimates 2- and 5-year risk of needing dialysis.
-
Why early matters
Referral and treatment before G4 meaningfully changes long-term trajectory.
Why this guide matters
Early treatment changes the trajectory.
A generation ago CKD was mostly monitored. Today, three drug classes — SGLT2 inhibitors, ACEi/ARBs and finerenone — meaningfully slow decline when started early.
-
Numbers matter
eGFR and ACR together predict progression more accurately than either on its own.
-
Cardiovascular risk is the main killer
Most people with CKD die of heart disease long before they reach dialysis — statins and BP matter.
-
Early referral pays off
Nephrology input before G4 lets you plan access, transplantation and conservative care calmly.
How the diagnosis is made
From first abnormal result to a settled plan.
The steps a UK GP or nephrology team will normally follow — so you know what to expect and why.
Phase 1 · Recognising
Baseline bloods and urine testing
Phase 2 · Confirming
Imaging and cause-finding tests
Phase 3 · Managing
Referral and cardiovascular risk
- 01
Recognising
Bloods — creatinine, eGFR, electrolytes
A baseline U&E panel establishes kidney function and picks up abnormal potassium or acidosis.
- 02
Recognising
Urine ACR (first morning)
The single most sensitive test for early kidney damage — a first-morning sample is best.
- 03
Recognising
Repeat to confirm chronicity
CKD requires an abnormality present for more than 3 months, not a single dip.
- 04
Confirming
Kidney ultrasound
If a structural cause is suspected — obstruction, stones, cysts or size asymmetry.
- 05
Confirming
Autoimmune, hepatitis and myeloma screen
Considered when eGFR is declining rapidly or the clinical picture points to a systemic cause.
- 06
Managing
Nephrology referral
From stage G3b onwards, or sooner if there is rapid decline, heavy proteinuria or an uncertain diagnosis.
- 07
Managing
Cardiovascular risk optimisation
CKD is a cardiovascular disease — statins, BP control and lifestyle are as important as kidney-specific drugs.
Typical timeline: 3–6 months from first abnormal result to a confirmed diagnosis and plan.
Symptoms
What CKD actually looks like.
Early CKD is almost always silent. When symptoms do appear, they matter — here is what to look for and when to seek urgent care.
-
Often asymptomatic
Most people with early CKD feel entirely well — it is usually picked up on routine bloods.
-
Ankle oedema
Swelling around the ankles, especially at the end of the day, can point to fluid retention.
-
Uraemic symptoms
Nausea, loss of appetite and itching appear in more advanced disease.
-
Breathlessness
From anaemia, fluid overload or coexistent cardiac disease.
-
Foamy urine
A visual clue to significant proteinuria — worth mentioning to your GP.
-
Anaemia of CKD
Reduced erythropoietin production leads to tiredness and pallor as kidney function falls.
-
Uncontrolled BP
CKD both causes and worsens hypertension — a persistent link that needs active management.
-
Red flag
Rapid eGFR drop, visible haematuria or systemic symptoms — arrange urgent nephrology assessment.
Treatment
How CKD is treated in the UK.
Layered treatment — protecting the kidneys, controlling risk factors and, when needed, planning renal replacement.
-
SGLT2 inhibitor
Dapagliflozin or empagliflozin — now standard for CKD with proteinuria, with or without diabetes.
-
ACE inhibitor or ARB
First-line for proteinuric CKD — lowers intra-glomerular pressure and slows decline.
-
Finerenone
A non-steroidal MRA licensed for diabetic CKD, added on top of ACEi/ARB and SGLT2i.
-
Statin
Recommended for most adults with CKD, regardless of baseline cholesterol.
-
BP target under 130/80
Tighter control than the general population — critical for slowing progression.
-
Anaemia management
Iron replacement and, if needed, erythropoiesis-stimulating agents (ESAs).
-
Bone-mineral disease
Monitoring and management of calcium, phosphate, PTH and vitamin D as CKD advances.
-
Nephrology follow-up
Long-term monitoring, and — if progressing — planned discussion of dialysis or transplantation.
What this guide is based on
The sources behind every number on this page.
UK national guidance, international consensus and specialist society standards, current at the time of last review.
Key references
Guidelines and standards we relied on.
A quiet reminder
This guide is for information, not medical advice.
Your GP or kidney team knows your history and can tell you which parts apply to you.
-
National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NG203).
-
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
-
UK Kidney Association (formerly Renal Association). Clinical practice guidelines.
-
NHS. Chronic kidney disease — overview and treatment.
Red flags
When kidney disease becomes urgent.
CKD is usually slow. These are the situations where it stops being slow — and you should act today.
-
Rapid eGFR decline
A fall of more than 25% or a category change within 12 months warrants urgent nephrology input.
-
Haematuria with proteinuria
Suggests glomerulonephritis and needs prompt specialist assessment and often biopsy.
-
Anti-GBM disease
A rare but rapidly destructive cause of kidney failure — treated as an emergency.
-
Multisystem features
Rash, joint pains, sinus disease or lung involvement can indicate ANCA-associated vasculitis.
-
Post-contrast AKI
A sudden creatinine rise after CT contrast or angiography needs same-day review.
-
Post-transplant complications
Any new symptom in a transplant recipient — always contact the transplant team first.
-
Nephrotic syndrome
Heavy proteinuria, low albumin and oedema — requires urgent specialist care.
-
Uraemic emergency
Confusion, pericarditis or intractable vomiting in advanced CKD — call 999.
-
Hyperkalaemia with ECG changes
Potassium over 6.5 mmol/L or ECG abnormalities is a medical emergency — attend A&E.
Living with it
A long-term condition, but a very manageable one.
Four things that make the biggest difference day to day — habits, monitoring, medication and reviews.
A quiet reminder
Consistency beats intensity, every time.
Small, steady changes — kept up for months — do more than a heroic week that does not last.
- 01 Daily habits
Salt, protein and hydration
Modest salt reduction, sensible protein intake and steady hydration are more useful than fads.
- 02 Monitoring
Know your numbers
Track eGFR and ACR trends — a stable trajectory is the goal, not a single number.
- 03 Medication
Sick-day rules
ACEi/ARB, SGLT2i, diuretics and metformin are usually paused during vomiting or dehydration — ask your team.
- 04 Reviews
Annual review, minimum
Yearly bloods, urine ACR, BP and cardiovascular risk check — more often in later stages.
Frequently asked
Everything we get asked about CKD.
Quick answers on staging, medications, monitoring and when specialist input is needed.
-
What eGFR level counts as chronic kidney disease?
An eGFR below 60 mL/min/1.73m² that persists for more than 3 months, or a urine albumin–creatinine ratio (ACR) of 3 mg/mmol or above, meets the definition of CKD (NICE NG203).
-
Does CKD always get worse?
No. Many people with early CKD have stable kidney function for decades, especially with good blood pressure control, an SGLT2 inhibitor and cardiovascular risk optimisation.
-
Why is a first-morning urine sample preferred for the ACR test?
A first-morning sample avoids the transient proteinuria that can occur after exercise or prolonged standing, giving a more accurate reading.
-
Can I take an SGLT2 inhibitor if I do not have diabetes?
Yes. Dapagliflozin and empagliflozin are licensed for CKD with proteinuria regardless of diabetes status, based on the DAPA-CKD and EMPA-KIDNEY trials.
-
What is the KFRE and why does it matter?
The Kidney Failure Risk Equation estimates your 2- and 5-year risk of needing dialysis or a transplant. It helps you and your team plan referrals, access and long-term decisions.
-
When should I be referred to a kidney specialist?
Usually from stage G3b (eGFR under 45), or sooner if there is rapid decline, heavy proteinuria, an uncertain diagnosis or a KFRE 5-year risk above about 5%.
Related content
Keep reading.
-
Kidney function tests
eGFR, ACR and what each result actually means.
Learn more -
Cardiovascular risk assessment
The single biggest driver of outcomes in CKD.
Learn more -
HbA1c — the diabetes test
Diabetes is a top cause of CKD — HbA1c tracks control.
Learn more -
All conditions
Browse every clinically reviewed condition guide.
Learn more